Literature DB >> 21265580

The correct administration of antihypertensive drugs according to the principles of clinical pharmacology.

Stefano Taddei1, Rosa Maria Bruno, Lorenzo Ghiadoni.   

Abstract

Control of cardiovascular (CV) risk factors, particularly hypertension, is still unsatisfactory, resulting in excess CV morbidity and mortality worldwide. CV risk is linearly associated with an increase in blood pressure (BP) values, and clinical studies have clearly demonstrated that BP lowering represents the most effective means of preventing CV events. However, while BP reduction is a fairly easy target, BP normalization is much more difficult to achieve, and adequate BP control (<140/90 mmHg) is attained only in a small percentage of the hypertensive population. One of the main reasons for the lack of efficacy of antihypertensive pharmacological treatment is that very often drugs are not administered at the correct dosage. In this review, we discuss the importance of using clinical pharmacology to guide treatment of hypertension. Controlled clinical trials, including HOPE, EUROPA, and CONSENSUS, are used to guide prescribing decisions. Unfortunately, the results obtained in pivotal studies such as these have been obtained using drug dosages much higher than those usually used in clinical practice. The prescription of a drug for the treatment of hypertension should take into consideration the potency of the drug, i.e. the degree of BP reduction required, and the duration of action of the drug, i.e. the need to cover the dosing interval (possibly 24 hours) in a homogeneous way. This is especially the case for angiotensin-converting enzyme (ACE) inhibitors, compounds characterized by a flat dose-response curve. The significance of this flat dose-response curve is that a low dose of an ACE inhibitor has the same potency as a high dose but a shorter duration of action. If a low dosage is administered to a hypertensive patient it causes BP fluctuations, which have been associated with negative CV outcomes. In contrast, other drug classes, including calcium channel antagonists, diuretics, and β-adrenoceptor antagonists, can be used at different dosages in order to modulate their hemodynamic effects. Thus, it is important to be aware of the clinical pharmacology of antihypertensive drugs in order to choose not only the class or the molecule best suited to the clinical characteristics of the patient, but also the correct dosages to ensure effective and homogeneous 24-hour BP reduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21265580     DOI: 10.2165/11586670-000000000-00000

Source DB:  PubMed          Journal:  Am J Cardiovasc Drugs        ISSN: 1175-3277            Impact factor:   3.571


  5 in total

1.  Clinical pharmacists and basic scientists: do patients and physicians need this collaboration?

Authors:  Amir H Zargarzadeh; Susan Jacob; Roger S Klotz; Fadi T Khasawneh
Journal:  Int J Clin Pharm       Date:  2011-12

Review 2.  Resistant Hypertension: A Real Entity Requiring Special Treatment?

Authors:  Stefano Taddei; Rosa Maria Bruno
Journal:  Eur Cardiol       Date:  2016-08

Review 3.  New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.

Authors:  Anjay Rastogi; Farid Arman; Setareh Alipourfetrati
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

4.  The older patient with hypertension: care and cure.

Authors:  Claudio Borghi; Elisa Tartagni
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

5.  How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study.

Authors:  Paola Cianfrone; Mariadelina Simeoni; Nicola Comi; Valentina Piraina; Roberta Talarico; Annamaria Cerantonio; Innocenza Gentile; Flora Fortunata Fabiano; Gaetano Lucisano; Daniela Foti; Elio Gulletta; Giorgio Fuiano
Journal:  J Nephrol       Date:  2015-12-26       Impact factor: 3.902

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.